BioSpace News Archive

Morrisville, North Carolina, has reason to hope that it may be the beneficiary of Fujifilm’s next major investment, a $2 Billion USD large-scale cell culture manufacturing site which the company said will be located near one of its current facilities.

Process development and quality control will begin in 2021, and full manufacturing capabilities at the 88,000-square-foot facility will be available in 2023.

Depending on your master’s program of interest and your personal qualifications, you might need to take months (or years) to develop into the type of candidate that is admitted.

In the run-up to January’s JP Morgan Healthcare Conference, BioSpace caught up with CEO Paul Wotton to discuss the company’s plans for 2021. More collaborations are key features.

Scientists at the University of Birmingham, UK, have shown that a novel low molecular weight dextran-sulphate, ILB could play a key role in treating open angle glaucoma (OAG), a neurodegenerative disease that affects over 70 million people worldwide and causes irreversible blindness.

Medicure Inc., a cardiovascular pharmaceutical company, announced that through its Barbados subsidiary, Medicure International Inc., it intends to file an Investigational New Drug application with the U.S. Food and Drug Administration pertaining to its legacy product Pyridoxal 5′-phosphate for the treatment of seizures associated with pyridoxine 5'-phosphate oxidase deficiency.

Apexigen, Inc., a clinical-stage biopharmaceutical company, announced that Xiaodong Yang, M.D., Ph.D., President and Chief Executive Officer, will participate in two upcoming virtual investor healthcare conferences

Cullinan Management, Inc., a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies with transformative potential for cancer patients, announced the pricing of its upsized initial public offering of 11,900,000 shares of common stock at a price to the public of $21.00 per share.

Shattuck Labs, Inc., a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, announced it will present at the H.C. Wainwright BioConnect 2021 Conference being held virtually January 11-14, 2021.

Novavax, Inc., a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, announced that it has executed an Advance Purchase Agreement with the Commonwealth of Australia for 51 million doses of NVX-CoV2373, Novavax’ COVID-19 vaccine candidate.